Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics of the cohort

From: Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

Summary data
Characteristic Cohort
Geographic origin Japan
Type of cohot Clinic-based
Centralized HER2 assessment no
Centralized clinical data collection no
Length of follow-up (months) 3.4-63.3
Total Number of patients 75
Parameter Number of patients (%)
HER2 status by IHC 75 (100)
HER2 status by FISH 9(12.0)
  Total Log 10 HER2 expression • Median Log 10 HER2 expression • Median
HER2 test at the local hospital    
2+ 20 (26.7) 11 (28.9) 9 (24.3)
3+ 55 (73.3) 27 (71.1) 28 (75.7)
Centrally reviewed IHC    
0 11 (14.7) 1 (2.6) 10 (27.0)
1+ 14 (18.7) 2 (5.3) 12 (32.4)
2+ 18 (24.0) 9 (23.7) 9 (24.3)
3+ 32 (42.7) 26 (68.4) 6 (16.2)
HER2 score on repeat testing    
Mean (s.d.) 148 (101) 210 (71) 84 (87)
Min - Max 0 - 290 0 - 290 0 - 290
Hormone receptor status    
ER+ PR+ 10 (13.3) 6 (15.8) 4 (10.8)
ER+ PR- 2 (2.7) 1 (2.6) 1 (2.7)
ER- PR+ 3 (4.0) 0 3 (8.1)
ER- PR- 60 (80.0) 31 (81.6) 29 (78.4)
ER unknown, PR- 0 0 0
ER unknown, PR unknown 0 0 0
Nodal status    
Negative 21 (28.0) 14 (36.8) 7 (18.9)
1 to 3 positive nodes 23 (30.7) 9 (23.7) 14 (37.8)
4 to 10 positive nodes 8 (10.7) 4 (10.5) 4 (10.8)
> 10 positive nodes 17 (22.0) 7 (18.4) 10 (27.0)
Status missing 6 (8.0) 4 (10.5) 2 (5.4)
Tumor size    
< = 2 cm 9 (12.0) 5 (13.2) 4 (10.8)
>2 cm & < = 5 cm 37 (49.3) 19 (50.0) 18 (48.7)
>5 cm 17 (22.7) 6 (15.8) 11 (29.7)
Missing 12 (16.0) 8 (21.1) 4 (10.8)
Prior adjuvant therapy    
Adj HT 30 (40.0) 15 (39.5) 15 (40.5)
Adj CT 51 (68.0) 23 (60.5) 28 (75.7)
Adj HT only 5 (6.7) 2 (5.3) 3 (8.1)
Adj CT only 26 (34.7) 10 (26.3) 16 (43.2)
Adj HT & Adj CT 25 (33.3) 13 (34.2) 12 (32.4)
neither HT nor CT 19 (25.3) 13 (34.2) 6 (16.2)
Number of pre-chemotherapy before trastuzumab treatment*    
0 41 (54.7) 18 (47.4) 23 (62.2)
1 15 (20.0) 9 (23.7) 6 (16.2)
2 or 3 7 (9.3) 3 (7.9) 4 (10.8)
N.A. 12 (16.0) 8 (21.1) 4 (10.8)
Tumor stage    
Recurrence 66 (88.0) 32 (84.2) 34 (91.9)
Advanced 9 (12.0) 6 (15.8) 3 (8.1)
Number of met sites    
1 or 2 49 (65.3) 25 (65.8) 24 (64.9)
3 or 4 25 (33.3) 12 (31.6) 13 (35.1)
unknown 1 (1.3) 1 (2.6) 0
Brain mets    
yes 7 (9.3) 5 (13.2) 2 (5.4)
no 68 (90.7) 33 (86.8) 35 (94.6)
Treatment    
Herceptin + chemo 63 (84.0) 31 (81.6) 32 (86.5)
Herceptin only 12 (16.0) 7 (13.5) 5 (18.4)
  1. * For the 66 patients with recurrence, the number of pre-chemotherapy received after recurrence was analyzed.